靶向细胞程序性死亡受体-1(programmed cell death protein-1,PD-1)/细胞程序性死亡配体-1(programmed cell death ligand-1,PD-L1)已成为最具前景的肿瘤免疫治疗靶点之一。目前,PD-1/PD-L1单克隆抗体药物及小分子抑制剂都面临着相应的...靶向细胞程序性死亡受体-1(programmed cell death protein-1,PD-1)/细胞程序性死亡配体-1(programmed cell death ligand-1,PD-L1)已成为最具前景的肿瘤免疫治疗靶点之一。目前,PD-1/PD-L1单克隆抗体药物及小分子抑制剂都面临着相应的发展瓶颈,许多研究者尝试探索不同的策略以阻断PD-L1/PD-L1通路,期望改善肿瘤治疗的效果。本文总结了靶向PD-L1的降解剂、双功能分子及共价抑制剂,旨在为PD-1/PD-L1药物的开发提供有益的思路。展开更多
1 文献来源Borghaei H,Langer CJ,Paz-Ares L,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression:A pooled analysis of 3 rand...1 文献来源Borghaei H,Langer CJ,Paz-Ares L,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression:A pooled analysis of 3 randomized controlled trials [J].Cancer,2020,126(22):4867-4877.2 证据水平1b。展开更多
文摘靶向细胞程序性死亡受体-1(programmed cell death protein-1,PD-1)/细胞程序性死亡配体-1(programmed cell death ligand-1,PD-L1)已成为最具前景的肿瘤免疫治疗靶点之一。目前,PD-1/PD-L1单克隆抗体药物及小分子抑制剂都面临着相应的发展瓶颈,许多研究者尝试探索不同的策略以阻断PD-L1/PD-L1通路,期望改善肿瘤治疗的效果。本文总结了靶向PD-L1的降解剂、双功能分子及共价抑制剂,旨在为PD-1/PD-L1药物的开发提供有益的思路。
文摘1 文献来源Borghaei H,Langer CJ,Paz-Ares L,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression:A pooled analysis of 3 randomized controlled trials [J].Cancer,2020,126(22):4867-4877.2 证据水平1b。
